	US 12,447,192 B1
	Stable cannabinoid-comprising nanoemulsions and methods of using the same
Pranav M. Patel, Land O Lakes, FL (US); and Navdeep Jaikaria, Titusville, NJ (US)
Assigned to SGN NANOPHARMA INC., Tampa, FL (US)
Filed by SGN Nanopharma Inc., Tampa, FL (US)
Filed on Aug. 13, 2021, as Appl. No. 17/401,826.
Claims priority of provisional application 63/065,756, filed on Aug. 14, 2020.
Int. Cl. A61K 38/13 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 31/05 (2006.01); A61K 31/352 (2006.01); A61K 47/44 (2017.01); A61P 27/04 (2006.01)

CPC A61K 38/13 (2013.01) [A61K 9/0048 (2013.01); A61K 9/1075 (2013.01); A61K 31/05 (2013.01); A61K 31/352 (2013.01); A61K 47/44 (2013.01); A61P 27/04 (2018.01)]

13 Claims

1. A nanoemulsion formulation, comprising:

(a) a pharmaceutically acceptable oil selected from olive oil, sesame and medium chain triglycerides, said oil having less than one part per million of each of copper, chromium, lithium and molybdenum; and

(b) a cannabinoid or a salt or derivative thereof dissolved in the pharmaceutically acceptable oil; the cannabinoid or salt or derivative thereof having a weight percentage of up to 45% of the nanoemulsion formulation,

wherein said cannabinoid or salt or derivative thereof in the nanoemulsion formulation is stable for at least 4 months when measured under accelerated chamber conditions.